Insider · CIK 0001350416

Kaye Randall

Reports to the SEC for 3 companies · ALISO VIEJO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001350416

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-12-02	Longboard Pharmaceuticals, Inc.Restricted Stock UnitD Disposition to Issuer	Executive Vice President & CMO	DDisposition to Issuer	−9,500 sh	—	—	0
2024-12-02	Longboard Pharmaceuticals, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	Executive Vice President & CMO	DDisposition to Issuer	−96.3K sh	—	—	0
2024-12-02	Longboard Pharmaceuticals, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	Executive Vice President & CMO	DDisposition to Issuer	−108K sh	—	—	0
2024-12-02	Longboard Pharmaceuticals, Inc.Restricted Stock UnitD Disposition to Issuer	Executive Vice President & CMO	DDisposition to Issuer	−17.9K sh	—	—	0
2024-12-02	Longboard Pharmaceuticals, Inc.U Disposition from Tender	Executive Vice President & CMO	UDisposition from Tender	−30.6K sh	$60.00	−$1.83M	0
2024-12-02	Longboard Pharmaceuticals, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	Executive Vice President & CMO	DDisposition to Issuer	−176K sh	—	—	0
2024-11-19	Longboard Pharmaceuticals, Inc.M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	+30.6K sh	$6.00	+$183K	48,474
2024-11-19	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	−30.6K sh	—	—	175,946
2024-10-25	Longboard Pharmaceuticals, Inc.Retention Restricted Stock UnitsA Award	Executive Vice President & CMO	AAward	+9,500 sh	—	—	9,500
2024-10-15	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−16.7K sh	$59.03	−$984K	17,920
2024-10-15	Longboard Pharmaceuticals, Inc.M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	+16.7K sh	$4.35	+$72.5K	34,587
2024-10-15	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	−16.7K sh	—	—	96,300
2024-09-16	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−4,200 sh	$31.81	−$134K	21,020
2024-09-16	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−1,200 sh	$33.12	−$39.7K	19,820
2024-09-16	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−1,900 sh	$34.04	−$64.7K	17,920
2024-09-16	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	−16.7K sh	—	—	112,967
2024-09-16	Longboard Pharmaceuticals, Inc.M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	+16.7K sh	$4.35	+$72.5K	34,586
2024-09-16	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−9,366 sh	$30.89	−$289K	25,220
2024-08-12	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−10.5K sh	$34.55	−$362K	24,111
2024-08-12	Longboard Pharmaceuticals, Inc.M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	+16.7K sh	$4.35	+$72.5K	34,587
2024-08-12	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Executive Vice President & CMO	MExercise/Conversion	−16.7K sh	—	—	129,633
2024-08-12	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−6,191 sh	$35.03	−$217K	17,920
2024-06-25	Longboard Pharmaceuticals, Inc.S Sale	Executive Vice President & CMO	SSale	−100 sh	$20.87	−$2,087	0
2024-02-08	Longboard Pharmaceuticals, Inc.A Award	Executive Vice President & CMO	AAward	+17.9K sh	—	—	17,920
2024-02-08	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)A Award	Executive Vice President & CMO	AAward	+108K sh	—	—	107,560
2024-01-23	Longboard Pharmaceuticals, Inc.P Purchase	Executive Vice President & CMO	PPurchase	+100 sh	$24.82	+$2,482	100
2023-02-09	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)A Award	Executive Vice President & CMO	AAward	+146K sh	—	—	146,300
2022-03-21	Longboard Pharmaceuticals, Inc.Stock Option (Right to Buy)A Award	Executive Vice President & CMO	AAward	+207K sh	—	—	206,500
2015-12-23	AXSMAxsome Therapeutics, Inc.P Purchase	Chief Medical Officer	PPurchase	+1,000 sh	$9.03	+$9,026	6,022
2015-11-24	AXSMAxsome Therapeutics, Inc.C Conversion	Chief Medical Officer	CConversion	+5,022 sh	$5.40	+$27.1K	5,022
2015-11-24	AXSMAxsome Therapeutics, Inc. · 8% Convertible NoteA Award	Chief Medical Officer	AAward	+5,022 sh	—	—	0
2011-09-09	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−100K sh	$2.75	−$275K	65,690
2011-01-05	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$4.05	−$40.5K	165,690
2010-12-13	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−1,446 sh	$3.92	−$5,668.32	175,690
2010-12-06	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$3.80	−$38K	177,136
2010-12-01	AVANIR PHARMACEUTICALS, INC.Stock Option (right to buy)A Award	Sr. VP, Chief Medical Officer	AAward	+100K sh	—	—	100,000
2010-12-01	AVANIR PHARMACEUTICALS, INC.A Award	Sr. VP, Chief Medical Officer	AAward	+17.5K sh	—	—	196,836
2010-11-05	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$4.76	−$47.6K	187,136
2010-10-05	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$3.23	−$32.3K	227,036
2010-09-13	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−1,447 sh	$2.70	−$3,906.9	237,036
2010-09-07	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$2.70	−$27K	238,483
2010-08-18	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−35K sh	$3.08	−$108K	248,483
2010-08-05	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$3.28	−$32.8K	283,483
2010-07-07	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−10K sh	$3.02	−$30.2K	293,483
2010-06-13	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−1,447 sh	$2.71	−$3,921.37	303,483
2010-06-07	AVANIR PHARMACEUTICALS, INC.S Sale	Sr. VP, Chief Medical Officer	SSale	−50K sh	$2.38	−$119K	304,930
2010-03-13	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−1,448 sh	$2.13	−$3,084.24	354,930
2010-01-04	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−28.5K sh	$1.97	−$56.1K	368,458
2010-01-04	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−28.1K sh	$1.97	−$55.3K	368,878
2009-12-13	AVANIR PHARMACEUTICALS, INC.F Tax Payment	Sr. VP, Chief Medical Officer	FTax Payment	−1,350 sh	$1.82	−$2,457	396,957

Recent filings

Accepted (ET)
Dec 24
Kaye Randall0001415889-24-028023
SEC(opens sec.gov)
Nov 194
Kaye Randall0000950170-24-128962
SEC(opens sec.gov)
Oct 294
Kaye Randall0000950170-24-118315
SEC(opens sec.gov)
Oct 164
Kaye Randall0000950170-24-115026
SEC(opens sec.gov)
Sep 164
Kaye Randall0000950170-24-106949
SEC(opens sec.gov)
Aug 134
Kaye Randall0000950170-24-096496
SEC(opens sec.gov)

Companies

Address

101 ENTERPRISE, SUITE 300

ALISO VIEJO, CA, 92656